4. CONCLUSION
Here, we reported the first case of piperacillin-tazobactam-induced immune thrombocytopenia successfully challenged by the use of meropenem and cefotiam, but cannot tolerant with cefoperazone-sulbactam for the treatment of pneumonia. Although the exact responsible antibodies of piperacillin-tazobactam-induced immune thrombocytopenia remain unknown and need further investigation, attention should be paid to the role of chemical structure similarities in determining the risk of DITP among beta-lactams in the clinical setting.